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Oncogene	 specificity	 represents	 the	 future	 of	 cancer	 therapy.	 Targeted	 drug	
development	 rests	 on	 the	belief	 that,	 since	 cancer	 cells	 are	 very	 similar	 to	 self,	 promiscuous	
chemotherapy	 agents	 have	 a	 narrow	 therapeutic	 window	 and	 therefore	 selectivity	 is	
paramount	 to	 achieving	 cures.	 Moreover,	 certain	 classes	 of	 cancer	 are	 resilient	 to	 some	
targeted	 therapies	 that	 are	 upstream	 or	 downstream	 of	 the	 cellular	 signaling	 pathway.	 For	
example,	many	 K-Ras-driven	 cancers	 are	 resistant	 to	 treatment	with	 EGFR	 inhibitors	 such	 as	
cetuximab.	Also,	despite	the	availability	of	clinically	approved	inhibitors	of	RAF	and	MEK,	which	




to	 achieve	 oncogene	 specificity.	 Cysteine	 is	 the	 most	 nucleophilic	 amino	 acid,	 rendering	 it	
amenable	 to	 covalent	 labeling	 by	 electrophilic	 warheads.	 These	 cysteine-selective	 warheads	
can	allow	the	small	molecule	a	long	residence	time	within	a	nearby	binding	pocket	and	render	







Ras	proteins	 are	part	 of	 a	 large	 superfamily	of	 small	monomeric	GTPases	 (20-25	 kDa)	
that	 act	 as	 a	 molecular	 switch	 to	 regulate	 cell	 growth	 and	 proliferation.	 Ras	 is	 activated	 in	
response	 to	 growth	 factors	 binding	 to	 the	 receptor	 tyrosine	 kinases,	 stimulating	 the	
autophosphorylation	of	 tyrosine	 residues	on	 that	 receptor	which	bind	 to	 the	adaptor	protein	
GRB2	 to	 recruit	 SOS	 to	 activate	 Ras.	 Anchored	 by	 a	 lipid	 tail	 to	 the	 cellular	membrane,	 Ras	
cycles	between	an	inactive	GDP-bound	state,	and	an	active	GTP-bound	state,	in	response	to	the	
cellular	 environment.	 Ras	 activation	 is	 positively	 regulated	 by	 Son	 of	 Sevenless	 (SOS)	 and	
negatively	 regulated	by	GTPase-activating	protein	 (GAP),	with	 a	 key	 role	being	played	by	 the	
10:1	GTP:GDP	nucleotide	 ratio	within	 the	cell.	Ras	 signaling	 is	dysregulated	 in	30%	of	human	
cancers1,	rendering	it	the	most	common	oncogenic	driver.		
Ras	is	a	small	globular	protein	and	consists	of	a	core	G	domain	and	a	flexible	C-terminal	





















biochemically	 similar	 in	 their	 constitutive	 activation	 of	 Ras,	 several	 biochemical	 studies	 have	















Ras.	K-Ras(G12C)	occurs	 in	40%	of	 lung	adenocarcinoma,	making	 it	a	highly	 important	 target.	
Despite	 the	 lack	 of	 biochemical	 data,	 selective	 targeting	 of	 K-Ras(G12C)	 has	 been	 achieved,	
driving	more	interest	in	the	biochemical	characterization	of	this	oncogene.	Ostrem	and	Peters	
demonstrated	 that	 K-Ras(G12C)	 can	 react	 irreversibly	 with	 covalent	 ligands	 that	 bind	 to	 a	
transient	pocket	under	the	switch-II	loop6	and	developed	G12C	inhibitors	using	fragment-based	
disulfide	tethering7.		
Through	 characterization	 of	 these	 early	 generation	 switch	 II	 pocket	 inhibitors,	 it	 was	
discovered	 that	G12C	still	participates	 in	nucleotide	cycling.	Therefore,	although	 the	 switch	 II	
pocket	 inhibitors	 bind	 preferentially	 to	 the	 GDP-bound	 state,	 they	 disrupt	 nucleotide	 cycling	
and	sequester	Ras	in	the	inactive	state	until	it	is	targeted	for	degradation.	It	was	shown	that	K-
Ras	mutants	such	as	K-Ras(G12C)	can	be	inhibited	by	an	allosteric	trapping	mechanism	in	order	
to	 kill	 patient	 derived	 K-Ras(G12C)	 lung	 adenocarcinoma	 cells6,8-10.	 	 Since	 then,	 Wellspring	





























its	 differential	 oncogenicity	 and	 clinical	 phenotype	 to	 similar	 transforming	 mutations	 like	
G12C18.	 To	 date,	 there	 are	 no	 crystal	 structures	 of	 the	 G13C	 mutant	 to	 characterize	 this	
 7	
oncogene.	Modeling	G13C	 into	 Ras	 presupposes	 that	 the	 cysteine	 rotamer	 is	 tilted	 from	 the	
switch	II	pocket,	like	its	G12C	predecessor.	Comparing	K-Ras(G12C)	and	K-Ras(G13D)	shows	that	
residue	 13	 is	 connected	 to	 the	 nucleotide	 binding	 pocket	 via	 a	 hydrogen	 bonding	 network,	
which	could	be	partially	disrupted	by	 the	mutation	 to	a	bulkier	mutant	 residue.	 	Biochemical	





The	 design	 of	 covalent	 inhibitors	 for	 known	 drug	 targets	 remains	 a	 difficult	 task.	 To	
avoid	hyper-reactive	 compounds,	most	high	 throughput	 screens	 (HTS)	 cautiously	 remove	any	
covalent	 compounds,	 barring	 canonical	 HTS	 as	 a	 screening	 method.	 Disulfide-tethering	 has	
been	successful	 for	 initial	development	and	proof	of	principle	of	G12C	 inhibitors	but	 requires	
multiple	 rounds	 of	 structure-activity-relationships	 to	 achieve	 a	 selective	 carbon-based	
electrophile	from	the	tethered	fragment.	Carbon-based	electrophile	 libraries	are	usually	small	
in	size	and	difficult	to	compare	in	terms	of	reactivity	to	various	targets.	With	the	advent	of	 in	
silico	 drug	 screening,	 covalent	 docking	 is	 furthermore	 also	 untested	 as	 an	 approach	 against	
difficult	 drug	 targets	 such	 as	 Ras.	 Most	 of	 the	 work	 described	 in	 the	 manuscript	 utilizes	 a	






Through	 the	 research	 shown	 in	 this	 thesis,	 covalent	 docking	 is	 applied	 to	 the	
traditionally	undruggable	target	Ras	and	is	described	as	a	new	method	to	find	a	different	class	
of	 Ras	 binders.	 The	 vast	 structural	 and	 chemical	 data	 was	 utilized	 on	 G12C	 to	 predict	 new	
binders	of	the	switch	II	pocket	(S-IIP)	using	covalent	docking14,15,17,18.		Millions	of	commercially	
available	compounds	were	used	to	dock	acrylamide	fragments	to	K-Ras(G12C).		From	this	data	
arose	 a	 docking	 predicted	 class	 of	 G12C	 binders	 that	 accelerate	 nucleotide	 exchange.	 These	
small	 molecules	 are	 predicted	 covalent	 docking	 binders	 that	 destabilize	 Ras	 upon	 binding,	
achieving	nucleotide	exchange	via	fluorescence-based	methods.		These	binders	label	G12C	with	
favorable	 potency	 and	 selectivity.	 These	 results	 prove	 that	 DOCKovalent	 is	 an	 appropriate	
























































































































































































Figure	2.2.2.	Docking	pose	of	disulfide	 tethering	hit,	6H05	a.	 Structure	of	disulfide	 tethering	
hit,	6H05.	b.	Docking	pose	of	6H05	(blue)	in	docking	model	(PDB:	4M1S	chain	B)	aligned	to	co-






































































































































































































































































































DOCK	pose	 (green)	 and	DOCKovalent	 pose	 (cyan)	 of	 compound	1	 overlay	 closely	with	 only	 a	
slight	 rotation	 of	 the	 amide	 bond	 in	 the	 pyrrolidine-2-carboxamide	 linker.	 b.	 Alignment	 of	

































































































































































 10 + Sos
11 + Sos
G12C - Sos































































































apo	 K-Ras(G12C)	 GDP	 represented	 on	 co-crystal	 structure	 with	 compound	 11	 (PDB	 4M21).	







































Difference between K-Ras(G12C) GDP and
K-Ras(G12C) GDP bound to Compound 11
Difference between K-Ras(G12C) GDP and

























(56.89 - 57.18°C) 11
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K-RasG12C T50 (95% Confidence) 















































































































































































S E Z RT Sequence 0.3s SD 3s SD 30s SD 300s SD 3000s SD 0.3s SD 3s SD 30s SD 300s SD 3000s SD 0.3s SD 3s SD 30s SD 300s SD 3000s SD
23 31 2 8.1 LIQNHFVDE 18.7 1.3 26.4 1.4 40.5 0.6 40.6 1.2 40.4 0.8 20.4 1.2 29.3 0.7 35.9 1.0 40.7 0.4 40.8 0.9 20.1 1.6 27.0 1.8 35.1 0.6 40.4 0.5 39.7 1.0 100
24 31 1 7.1 IQNHFVDE 19.3 0.8 27.0 0.9 36.0 0.6 35.4 1.0 34.7 1.0 20.9 1.1 29.6 0.8 33.8 0.9 34.8 0.7 34.6 0.4 20.7 0.6 27.7 1.8 33.9 1.0 34.7 0.4 34.0 0.5 90
24 37 2 9.8 IQNHFVDEYDPTIE 21.8 1.7 35.0 1.0 44.4 0.7 44.5 1.0 43.9 0.6 25.0 1.6 38.0 1.0 43.4 0.7 44.4 0.4 44.3 1.1 23.9 1.4 35.3 1.5 43.6 0.5 44.1 0.4 44.1 0.9 80
24 38 2 9.7 IQNHFVDEYDPTIED 20.7 1.7 32.8 1.8 42.2 0.8 42.2 1.2 41.5 0.5 23.5 1.8 35.6 1.2 40.7 0.6 41.7 0.6 41.8 1.5 22.2 1.7 33.2 1.5 40.5 0.3 41.2 0.5 41.5 1.2 70
24 39 2 9.7 IQNHFVDEYDPTIEDS 20.9 1.8 34.5 1.5 45.0 0.8 43.8 1.3 42.5 0.6 24.1 1.8 37.8 0.8 43.1 0.8 43.7 1.0 42.7 1.5 22.3 1.2 34.7 1.6 44.1 0.4 43.8 1.0 43.1 1.9 60
29 38 1 8.4 VDEYDPTIED 23.9 2.1 40.0 0.5 47.4 1.5 46.8 1.0 44.8 1.3 26.5 1.2 42.1 0.6 44.9 1.3 44.7 1.7 42.5 1.5 24.5 3.1 39.4 2.7 44.9 1.2 43.6 1.2 40.3 0.0 50
32 39 1 7.1 YDPTIEDS 29.8 2.2 53.9 1.4 68.8 1.4 68.1 1.1 67.4 1.9 35.3 2.1 59.8 0.3 66.3 0.9 67.4 0.4 66.5 1.3 31.3 2.1 54.6 3.8 66.8 1.0 66.8 0.8 64.8 0.7 40
34 39 1 5.2 PTIEDS 32.8 0.6 55.4 2.1 70.6 1.2 71.1 0.7 68.4 2.4 39.1 2.0 62.3 0.8 68.6 1.3 68.9 0.7 68.0 0.6 35.4 2.2 57.4 4.3 68.9 1.2 68.9 1.9 65.8 0.8 30
38 52 2 8.4 DSYRKQVVIDGETSL 26.1 1.4 35.1 1.6 52.6 0.8 64.8 0.9 72.2 1.0 25.9 1.1 36.2 0.4 42.4 0.4 67.7 0.4 73.2 0.1 26.7 0.3 35.7 1.2 41.8 0.3 61.4 0.3 72.6 0.6 20
39 52 3 8.0 SYRKQVVIDGETSL 25.4 1.1 33.4 1.3 49.6 0.5 62.4 1.2 70.4 0.7 25.7 1.0 34.1 0.4 39.3 0.8 65.3 1.0 71.9 0.3 27.8 1.7 34.0 1.2 38.4 0.5 58.9 0.8 71.2 1.0 10
40 52 2 7.9 YRKQVVIDGETSL 25.8 1.0 32.6 1.1 47.3 0.6 61.0 0.9 69.5 0.6 26.1 1.0 33.3 0.3 36.9 0.6 63.9 1.0 71.2 0.5 27.9 1.2 33.1 1.0 36.0 0.5 57.2 0.7 70.5 0.9 0
53 63 1 10.1 LDILDTAGQEE 24.8 1.1 31.5 1.9 46.3 1.1 55.7 1.6 61.7 0.8 24.6 1.5 33.0 1.3 38.9 0.4 53.8 1.4 62.9 1.3 24.4 0.5 32.3 1.3 38.7 0.3 47.6 0.8 60.8 0.8
54 80 3 13.3 DILDTAGQEEYSAMRDQYMRTGEGFLL 33.0 0.8 44.2 0.8 55.0 0.8 58.3 1.3 60.6 0.5 32.1 1.3 45.0 0.9 53.3 1.0 58.3 1.0 62.0 0.0 33.2 1.6 42.7 1.2 53.3 0.6 56.1 0.9 61.6 1.6
57 67 1 8.0 DTAGQEEYSAM 57.0 0.6 60.8 0.9 66.1 0.4 65.6 1.4 64.8 1.0 56.3 1.7 61.3 1.8 65.5 1.1 66.2 0.3 65.8 0.6 56.8 0.8 61.9 1.5 65.7 1.4 66.0 0.4 65.7 0.8
68 79 3 9.8 RDQYMRTGEGFL 11.5 1.1 20.9 0.9 32.8 0.6 33.3 0.6 35.9 0.3 10.3 0.6 20.6 0.4 32.5 0.4 34.3 0.3 38.3 0.4 10.6 0.6 18.8 0.9 31.7 0.4 33.5 0.2 36.0 0.5
72 79 2 9.7 MRTGEGFL 11.2 0.7 15.0 0.6 18.7 0.4 19.5 0.4 23.4 0.3 9.9 0.5 14.7 0.6 19.0 0.3 20.6 0.3 26.9 0.3 10.3 0.6 14.2 0.3 18.7 0.2 19.6 0.1 23.6 0.3
82 113 5 9.6 FAINNTKSFEDIHHYREQIKRVKDSEDVPMVL 7.1 0.6 8.5 0.5 9.9 0.4 15.9 0.7 26.2 0.6 7.8 0.4 8.4 0.6 10.7 0.4 18.7 0.5 31.5 0.5 7.7 0.2 8.5 0.2 9.8 0.3 15.6 0.2 25.7 1.3
83 90 1 6.3 AINNTKSF 24.3 0.6 27.1 0.5 30.8 0.3 51.7 1.0 66.9 1.1 25.4 0.9 27.7 0.1 31.0 0.2 57.3 1.1 69.1 0.4 26.1 0.2 27.6 0.7 31.2 0.5 54.8 1.0 68.6 1.1
83 91 2 6.3 AINNTKSFE 20.9 0.4 23.0 0.6 26.0 0.5 44.2 0.8 60.1 1.1 21.5 0.6 23.4 0.5 26.6 0.4 51.4 1.1 66.9 0.1 21.8 0.4 23.6 0.7 26.5 0.3 47.6 0.7 64.2 1.2
83 113 5 9.1 AINNTKSFEDIHHYREQIKRVKDSEDVPMVL 7.5 0.7 9.0 0.2 10.3 0.4 15.6 0.8 25.7 0.8 8.2 0.4 8.8 0.6 10.9 0.6 18.1 0.5 29.7 0.4 8.1 0.3 8.9 0.4 10.2 0.3 15.3 0.3 24.6 1.2
90 113 5 9.2 FEDIHHYREQIKRVKDSEDVPMVL 9.0 0.8 10.8 0.6 12.5 0.5 18.3 0.8 29.7 1.1 9.9 0.4 10.6 0.7 13.3 0.7 20.5 0.6 33.6 0.4 9.7 0.4 10.8 0.5 12.4 0.4 17.5 0.3 27.4 0.7
91 113 4 8.6 EDIHHYREQIKRVKDSEDVPMVL 9.6 0.8 11.3 0.6 13.2 0.4 19.2 0.8 30.3 0.9 10.3 0.4 11.2 0.7 14.1 0.7 21.2 0.6 34.0 0.3 10.1 0.5 11.6 0.6 13.0 0.5 18.0 0.4 28.0 0.7
92 113 3 8.5 DIHHYREQIKRVKDSEDVPMVL 10.0 0.7 11.8 0.6 13.7 0.4 19.9 0.8 31.0 0.9 10.7 0.5 11.6 0.7 14.5 0.7 21.6 0.5 34.2 0.2 10.5 0.4 12.0 0.6 13.5 0.4 18.4 0.4 28.4 0.8
114 124 3 4.6 VGNKSDLPSRT 22.9 0.6 27.9 0.5 34.2 0.0 43.0 0.3 56.4 1.7 23.6 0.9 28.9 0.1 34.3 0.5 47.1 0.5 62.0 1.0 25.0 0.2 29.9 1.4 34.1 0.4 47.0 1.2 60.8 1.6
114 126 3 5.3 VGNKSDLPSRTVD 20.6 0.8 26.9 0.9 34.9 0.2 47.6 0.6 58.0 1.4 21.1 0.8 28.1 0.3 34.8 0.5 50.5 0.9 61.6 0.3 23.4 0.3 29.2 1.4 35.2 0.5 50.2 1.1 60.9 1.1
114 132 3 5.0 VGNKSDLPSRTVDTKQAQD 19.1 0.9 26.1 0.6 34.1 0.4 44.4 0.4 55.9 1.6 20.2 0.8 27.0 0.6 34.0 0.6 48.9 0.8 62.2 0.4 22.0 0.1 27.9 1.1 34.4 0.7 46.5 0.8 59.5 1.7
114 133 3 6.7 VGNKSDLPSRTVDTKQAQDL 16.2 0.7 22.4 0.5 29.9 0.4 39.0 0.6 50.1 0.7 17.1 0.9 23.0 0.4 29.8 0.5 44.0 1.1 58.1 0.0 18.5 0.5 23.8 1.0 30.0 0.9 40.8 0.8 53.6 1.3
114 144 5 11.1 VGNKSDLPSRTVDTKQAQDLARSYGIPFIET 7.4 0.5 11.1 0.4 16.9 0.3 28.6 0.7 41.0 0.1 8.4 0.5 11.4 0.4 17.2 0.3 34.9 0.8 52.9 0.2 9.0 0.2 11.3 0.3 17.6 0.1 30.3 0.1 44.0 1.3
133 144 2 11.6 LARSYGIPFIET 1.7 0.1 2.4 0.1 7.5 0.1 24.5 0.2 39.3 0.1 2.0 0.3 2.5 0.1 8.0 0.2 31.4 0.6 51.6 0.0 1.9 0.2 2.7 0.1 8.5 0.1 26.0 0.2 41.2 0.6
134 144 2 11.2 ARSYGIPFIET 2.0 0.1 2.6 0.1 7.9 0.2 25.6 0.2 41.4 0.2 2.3 0.4 2.9 0.2 8.5 0.1 32.6 0.8 52.2 0.0 2.2 0.1 3.1 0.1 9.0 0.1 27.1 0.1 43.1 0.6
134 156 3 10.5 ARSYGIPFIETSAKTRQGVDDAF 3.5 0.2 4.4 0.2 11.0 0.1 26.3 0.7 38.1 0.1 4.0 0.3 4.6 0.2 10.6 0.1 30.8 0.1 43.5 0.2 3.8 0.2 4.7 0.1 10.7 0.1 27.6 0.3 39.3 0.9
137 144 1 12.5 YGIPFIET 1.7 0.2 2.6 0.2 9.6 0.1 27.9 0.0 38.4 0.2 2.5 0.9 2.8 0.2 10.3 0.3 32.0 0.7 47.7 0.1 3.0 0.7 3.3 0.1 10.9 0.1 28.3 0.0 38.3 0.3
145 156 2 6.8 SAKTRQGVDDAF 7.2 0.2 8.5 0.1 18.2 0.4 35.8 1.0 45.4 0.8 7.5 0.3 9.0 0.2 16.6 0.4 38.6 1.1 49.3 0.3 7.5 0.1 9.1 0.5 16.6 0.5 35.3 1.2 45.6 1.0
157 169 3 4.5 YTLVREIRKHKEK 1.5 0.1 2.6 0.1 7.8 0.1 12.4 0.1 13.8 1.4 1.7 0.2 2.8 0.2 7.7 0.3 12.2 0.4 15.1 0.7 1.8 0.1 3.0 0.3 7.7 0.3 11.7 0.5 14.0 1.2
160 169 3 2.7 VREIRKHKEK 2.9 0.2 4.9 0.2 12.0 0.2 18.2 0.4 21.3 0.7 3.0 0.4 5.4 0.6 12.1 1.3 17.9 0.8 20.1 2.7 3.4 0.6 5.5 1.2 12.7 0.6 17.1 1.6 19.8 2.5




























Figure	 2.10.2.	 Relative	 %deuterium	 incorporation	 over	 time	 in	 a.	 	 peptides	 34-39	 (Switch-I	











































































































4M21	chain	B	 4M1S	chain	B		 4M22	chain	B	 56A	chain	B*	
4LYJ	 4LUC	chain	A		 4M22	chain	C	 56A	chain	C*	
4LYH	chain	B		 4LUC	chain	B	 4M1T	chain	B		 56A	chain	D*	
4LYH	chain	C		 4LV6	chain	A		 59	chain	B*	 56A	chain	E*	
4LYF	chain	B		 4LV6	chain	B		 59	chain	C*	 55_P1	chain	A*	



















S1-1	 287.40	 0	 0	
	
S1-2	 295.38	 0	 0	
	
S1-3	 255.31	 0	 0	
	
S1-4	 281.35	 0	 0	
	
S1-5	 293.36	 0	 61.7	
	

































S1-7	 255.31	 0	 24.2	
	
S1-8	 243.26	 0	 0	
	
S1-9	 290.33	 0	 0	
	
S1-10	 271.31	 0	 0	
	








	 298.42	 0	 0	
	
2	 289.40	 20	 0	
	
S1-14	 290.36	 0	 0	
	
1	 294.35	 41	 43.5	
	
S1-15	
	 262.73	 0	 0	
	
S1-16	
	 273.33	 0	 23.6	
	





























































	 S1-18	 281.31	 0	 0	
	
S1-19	 272.27	 0	 0	
	
S1-20	 296.39	 0	 0	
	
S1-21	 273.29	 0	 20.2	
	
S1-22	 296.37	 0	 0	
	
S1-23	 296.36	 0	 21.4	
	 S1-24	 297.39	 0	 0	
	
S1-25	 265.74	 0	 0	
	
S1-26	 246.31	 0	 0	
	


































































DKM-2-31	 161.20	 0	 0	
	
DKM-2-32	 203.28	 0	 0	
	
DKM-2-34	 179.19	 0	 0	
	
DKM-2-37	 237.30	 0	 0	
	
DKM-2-39	 212.25	 0	 18.2	
	
DKM-2-40	 183.15	 40.4	 100	
	
DKM-2-43	 240.10	 0	 0	
	
DKM-2-47	 189.25	 0	 0	
	
DKM-2-49	 141.17	 0	 22.4	
	
DKM-2-50	 189.25	 0	 0	
	



















































DKM-2-59	 237.30	 0	 0	
	
DKM-2-60	 195.65	 0	 0	
	
DKM-2-84	 187.24	 0	 30.0	
	
DKM-2-85	 219.24	 56.5	 100	
	
DKM-2-86	 191.18	 0	 38.0	
	
DKM-2-87	 205.21	 0	 40.0	
	
DKM-2-95	 175.23	 0	 0	
	
DKM-2-97	 215.29	 0	 0	
	
DKM-2-98	 248.28	 0	 0	
	 DKM-2-99	 111.14	 0	 0	
	
DKM-2-100	 184.24	 0	 0	
	
DKM-2-101	 173.21	 41.7	 100	





















































	 DKM-2-103	 143.18	 0	 0	
	
DKM-2-104	 192.17	 100	 100	
	
DKM-2-107	 181.62	 0	 31.0	
	 DKM-2-108	 139.19	 0	 0	
	
DKM-2-109	 169.22	 0	 0	
	
DKM-2-110	 221.25	 0	 0	
	
DKM-2-111	 240.30	 0	 0	
	
DKM-2-113	 191.23	 0	 0	
	
DKM-2-114	 235.37	 0	 0	
	
DKM-2-116	 229.20	 0	 0	
	
DKM-2-117	 251.28	 100	 100	
	
DKM-2-119	 239.27	 38.8	 43	
	
DKM-2-120	 211.26	 0	 0	
	

































































DKM-3-4	 237.30	 0	 0	
	
DKM-3-5	 216.28	 0	 15.7	
	
DKM-3-7	 189.21	 53	 100	
	
DKM-3-8	 153.22	 0	 0	
	
DKM-3-9	 187.24	 0	 0	
	
DKM-3-10	 193.27	 0	 62.5	
	
DKM-3-12	 144.21	 0	 0	
	
DKM-3-15	 155.19	 0	 0	
	
DKM-3-16	 251.32	 0	 0	
	 DKM3-30	 273.71	 0	 0	
	
DKM3-31	 165.16	 0	 41.6	
	 DKM-3-32	 127.18	 0	 0	
	


























































DKM-3-41	 313.39	 0	 0	
	 DKM-3-42	 207.31	 0	 0	
	
DKM-3-43	 205.21	 0	 0	
	
DKM3-70	 223.27	 52	 100	
	
TRH-1-12	 211.34	 0	 0	
	
TRH-1-13	 221.25	 0	 0	
	
TRH-1-19	 147.17	 0	 28.2	
	
TRH-1-20	 175.23	 0	 0	
	
TRH-1-27	 167.25	 0	 0	
	
TRH-1-30	 157.23	 0	 24.5	
	


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































021617 Covalent Nucleotide Assay




















































































































































































































































































































































































































































































































































































































































































































































































































200uM 100uM 50uM 10uM
PCM-0102492 50 30 10 0
PCM-0102366 10 5 0 0
PCM-0102308 100 95 70 30
PCM-0102332 65 60 30 5
PCM-0102813 15 5 0 0
PCM-0102705 10 0 0 0
Ind1 100 90 60 10
Ind2 70 80 80 60
Ind3 100 100 90 20
PCM-0102690 0 0 0 0
PCM-0102923 0 0 0 0
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